


## ELOVL1-IN-1

<b>Cat. No.:</b>	HY-145122
<b>CAS No.:</b>	2227482-41-7
<b>Molecular Formula:</b>	C <sub>18</sub> H <sub>14</sub> F <sub>2</sub> N <sub>4</sub> O
<b>Molecular Weight:</b>	340
<b>Target:</b>	Others
<b>Pathway:</b>	Others
<b>Storage:</b>	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (294.12 mM; Need ultrasonic)					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
		<b>1 mM</b>		2.9412 mL	14.7059 mL	29.4118 mL
		<b>5 mM</b>		0.5882 mL	2.9412 mL	5.8824 mL
<b>10 mM</b>		0.2941 mL	1.4706 mL	2.9412 mL		
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.35 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (7.35 mM); Suspended solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (7.35 mM); Clear solution					

### BIOLOGICAL ACTIVITY

<b>Description</b>	ELOVL1-IN-1 is an ELOVL1 inhibitor extracted from patent WO2018107056A1, compound 87. ELOVL1-IN-1 can reduce very long chain fatty acid levels. ELOVL1-IN-1 can be used for the research of adrenoleukodystrophy (ALD) <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	ELOVL1 <sup>[1]</sup>
<b>In Vitro</b>	ELOVL1-IN-1 (compound 87) (1 nM-10 μM; 48 h) reduces the the level of VLCFA, lysophosphatidylcholine (LPC) in adrenoleukodystrophy (ALD) patient fibroblasts and healthy human fibroblasts, ALD patient B lymphocytes, and human microglia <sup>[1]</sup> .

---

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**In Vivo**

ELOVL1-IN-1 (compound 87) reduces of a VLCFA level, specifically C26:0 LPC level in blood of ABCD1 knockout (KO) mice (0.5-64 mg/kg; p.o. once daily for 28 days), wildtype (WT) rats (30-300 mg/kg; p.o. once daily for 7 days), and cynomolgous monkeys (30 mg/kg; p.o. once daily for 7 days)<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

**REFERENCES**

[1]. Charifson PS, et, al. 1,3-substitued pyrazole compounds useful for reduction of very long chain fatty acic levels. WO2018107056A1.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA